Efficacy of n‐3 polyunsaturated fatty acids after myocardial infarction: Results of GISSI‐prevenzione trial
- 1 January 2001
- Vol. 36 (S1), S119-S126
- https://doi.org/10.1007/s11745-001-0694-8
Abstract
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio (GISSI)-Prevenzione was conceived as a population, pragmatic trial on patients with recent myocardial infarctions conducted in the framework of the Italian public health system. In GISSI-Prevenzione, patients were invited to follow Mediterranean dietary habits, and were treated with up-to-date preventive pharmacological interventions. Long-term n-3 PUFA (1 g daily) but not vitamin E (300 mg daily), was beneficial for death and for combined death, nonfatal myocardial infarction, and stroke. All the benefit, however, was attributable to the decrease in risk for overall, cardiovascular, cardiac, coronary, and sudden death. At variance with the orientation of a scientific scenario largely dominated by the “cholesterol-heart hypothesis”, GISSI-Prevenzione results indicate n-3 PUFA (virtually devoid of any cholesterol-lowering effect) as a relevant pharmacological treatment for secondary prevention after myocardial infarction. As to the relevance and comparability of GISSI-Prevenzione results, up to 5.7 lives could be saved every 1000 patients with previous myocardial infarction treated with n-3 PUFA (1 g daily) per year. Such a result is comparable to that observed in the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial, where 5.2 lives could be saved per 1000 hypercholesterolemic, coronary heart disease patients treated with pravastatin for 1 yr. The choice of a relatively low-dose regimen (1-g capsule daily) more acceptable for long-term treatment in a population of patients following Mediterranean dietary habits, and the pattern of effects seen in GISSI-Prevenzione (namely, reduction of overall mortality with no decrease in the rate of nonfatal myocardial infarction) all strongly suggest that n-3 PUFA treatment should be considered a recommended new component of secondary prevention. The importance of this combined/additive effect is further suggested by the analyses of the interplay between diet and n-3 PUFA: There is an interesting direct correlation between size of the effect and “correctness” of background diets. It can be anticipated that a conceptual barrier must be overcome: A “dietary drug” should be added to “dietary advice”, which remains fundamental to allow this statement to become true in clinical practice.Keywords
This publication has 71 references indexed in Scilit:
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998
- Effects of dietary fish oil on ventricular premature complexesThe American Journal of Cardiology, 1995
- Prevention and Termination of β-Adrenergic Agonist-Induced Arrhythmias by Free Polyunsaturated Fatty Acids in Neonatal Rat Cardiac MyocytesBiochemical and Biophysical Research Communications, 1995
- Supplementation With Low Doses of Vitamin E Protects LDL From Lipid Peroxidation in Men and WomenArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein and high-density lipoprotein to oxidative modification.Journal of the American College of Nutrition, 1995
- Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkeyAmerican Heart Journal, 1992
- Beyond CholesterolThe New England Journal of Medicine, 1989
- Book ReviewAmbulatory Pediatric CareThe New England Journal of Medicine, 1989
- The Inverse Relation between Fish Consumption and 20-Year Mortality from Coronary Heart DiseaseThe New England Journal of Medicine, 1985
- The Composition of Food Consumed by Greenland EskimosActa Medica Scandinavica, 1976